| | By Gabrielle Masson AbbVie has inked a pact with Gilgamesh Pharmaceuticals aimed at developing next-gen therapies for psychiatric disorders. |
|
|
|
By Angus Liu When Bayer unveiled a restructuring in January, the company didn't provide specifics on the number of planned job cuts. Now, the size of the initial round of cuts shows that CEO Bill Anderson means business. |
By Nick Paul Taylor MacroGenics’ safety woes have followed into phase 2. Having dialed down the dose in response to early-phase data, the biotech's stock cratered after reporting five deaths alongside an over 50% rate of grade 3 or worse adverse events. |
By Fraiser Kansteiner AGC Biologics, which employs more than 2,500 workers worldwide, has “had to reduce positions at our Seattle and Colorado sites and global functional areas,” a spokesperson confirmed Friday in an emailed statement. The percentage of planned cuts suggests AGC could ultimately lay off around 100 employees. |
By Conor Hale The separate self-collection offerings from BD and Roche still need to be used in a healthcare setting—they have not received agency green lights for solo, at-home use. |
By Annalee Armstrong Linda Burkly, Ph.D., was 37 years into a career at Biogen when Editas CEO Gilmore O’Neill—himself an alum of the neurological disease-focused big biotech—came knocking. |
By Angus Liu Right after an industry survey suggested that switching away from Chinese CDMOs could take biopharma companies up to eight years, lawmakers have adjusted the BIOSECURE Act. The new draft lays out a 2032 deadline for the separation mandate and adds WuXi Biologics to the list of targets. |
By Kevin Dunleavy Sanofi has earmarked more than 1 billion euros ($1.1 billion) to increase its manufacturing capacity at three sites in France, while Pfizer ($540 million) and AstraZeneca ($394 million) halve also revealed significant investments in the country as part of its "Choose France" summit. |
By Andrea Park Roche’s long-awaited challenge to Regeneron’s dominance in the ophthalmology market may soon be coming to a head, according to a recent analyst report from GlobalData. |
By Helen Floersh While success for prenatal cell therapies has so far been limited to a handful of case studies, every failure brings the science one step closer to translation. That progress comes with ethical concerns. |
Fierce podcasts Don’t miss an episode |
| In this week’s episode of "Podnosis," Paige Minemyer and Dave Muoio, two journalists from the Fierce Healthcare team, dive into first-quarter earnings updates from some of the largest health plans and health systems, sharing their key insights and the trends they've identified. |
|
|---|
|
|
Research Download this research report to discover a new predictive model built on consumer attitudinal data can generate improved results for health marketers. Sponsored by: Quad Media |
Whitepaper In this free white paper, discover how consumer health and pharma leaders are harnessing the power of virtual care platforms and clinical networks to break down barriers to care, enhance accessibility, and revolutionize the patient / consumer experience - ultimately redefining the landscape of healthcare delivery. Sponsored by: Wheel |
Whitepaper How one top pharma increased literature reviews efficiency by 3x powered by AI -- download today Sponsored by: IQVIA |
Whitepaper Precision collection of cell therapy source material doesn’t happen by chance. Our new whitepaper illuminates the science and strategies for successful apheresis. Sponsored by: Comprehensive Cell Solutions |
Whitepaper Learn how Specifica’s in vitro antibody discovery platform can deliver better antibodies than traditional immunization approaches. Sponsored by: Specifica, a Q2 Solutions company |
Whitepaper Small molecule active pharmaceutical ingredients (APIs) continue to grow more complex. Download the white paper to learn more about using synthesis and route design technology to approach API complexity. Presented by: Lonza |
Whitepaper This paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead. Sponsored by: PPD®️ Laboratory Services |
eBook To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
Whitepaper Discover the secrets behind successful patient engagement Sponsored by: ProofPilot |
Whitepaper Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your copy today! Sponsored by: Sengenics Corporation LLC |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download now to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by: Lonza |
eBook Life sciences market experts from Optum and Advisory Board share perspectives on trends that will influence the future drug value chain. Download this eBook to learn more about the future state of health care dynamics and its affects along the pharmaceutical value chain. Presented by Optum Life Sciences and Advisory Board |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
